Please login to the form below

Not currently logged in
Email:
Password:

Tudorza

This page shows the latest Tudorza news and features for those working in and with pharma, biotech and healthcare.

Circassia seeks shift to AIM after failing LSE criteria

Circassia seeks shift to AIM after failing LSE criteria

AZ’s booked sales for Tudorza fell more than 50% to $18m in the third quarter. ... The agreement between Circassia and AZ also includes a deferred Tudorza option payment of $20m payable upon approval of Duaklir, plus a deferred consideration of $100m.

Latest news

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    If Circassia sublicenses the rights to Tudorza in the US, it will pay a further $80m. ... 250. AstraZeneca. Circassia Pharmaceuticals. Strategic collaboration. Tudorza (marketed) and Duaklir (phase III) in COPD.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics